Tsukasa Seya Selected Research

RNA Virus Infections

2/2014	MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells.
11/2011	The TLR3/TICAM-1 pathway is mandatory for innate immune responses to poliovirus infection.
12/2010	The ubiquitin ligase Riplet is essential for RIG-I-dependent innate immune responses to RNA virus infection.
1/2010	IL-6 and IFN-alpha from dsRNA-stimulated dendritic cells control expansion of regulatory T cells.
11/2008	Pan-vertebrate toll-like receptors during evolution.
10/2007	Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tsukasa Seya Research Topics

Disease

45	Neoplasms (Cancer) 01/2020 - 01/2002
38	Infections 01/2022 - 07/2002
22	Virus Diseases (Viral Diseases) 07/2017 - 02/2002
17	Inflammation (Inflammations) 01/2020 - 06/2008
11	Melanoma (Melanoma, Malignant) 01/2018 - 12/2006
7	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2020 - 12/2012
6	Bites and Stings (Sting) 04/2018 - 01/2013
6	RNA Virus Infections 02/2014 - 10/2007
4	Bacterial Infections (Bacterial Infection) 07/2017 - 11/2004
4	Hepatocellular Carcinoma (Hepatoma) 12/2007 - 01/2002
3	Human Influenza (Influenza) 12/2018 - 12/2017
3	Autoimmune Diseases (Autoimmune Disease) 01/2018 - 01/2011
3	Necrosis 01/2013 - 05/2011
3	Vesicular Stomatitis 01/2009 - 08/2003
2	Lewis Lung Carcinoma 04/2018 - 05/2016
2	T-Cell Leukemia (Leukemia, T Cell) 01/2017 - 11/2005
2	Carcinogenesis 04/2013 - 10/2010
2	Leukemia 06/2011 - 11/2005
2	Lymphoma (Lymphomas) 05/2011 - 01/2006
2	Experimental Melanoma 04/2011 - 10/2010
2	Subacute Sclerosing Panencephalitis (SSPE) 12/2007 - 08/2003
1	Body Weight (Weight, Body) 01/2022
1	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 01/2022
1	Severe Acute Respiratory Syndrome 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2018
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2018
1	Polyps 10/2017
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2017
1	Septic Shock (Toxic Shock Syndrome) 01/2017

Drug/Important Bio-Agent (IBA)

20	Proteins (Proteins, Gene)FDA Link 07/2018 - 08/2002
19	RNA (Ribonucleic Acid)IBA 01/2018 - 01/2004
18	CytokinesIBA 01/2019 - 01/2004
17	AntigensIBA 01/2020 - 11/2003
17	Antiviral Agents (Antivirals)IBA 07/2018 - 02/2006
17	Interferon Type IIBA 01/2018 - 08/2009
16	LigandsIBA 01/2019 - 10/2007
15	Double-Stranded RNA (RNA, Double Stranded)IBA 04/2018 - 05/2002
14	Pattern Recognition ReceptorsIBA 01/2020 - 12/2006
13	Toll-Like Receptors (Toll-Like Receptor)IBA 07/2018 - 11/2003
13	InterferonsIBA 04/2018 - 09/2011
11	Poly I-CIBA 04/2018 - 12/2006
10	VaccinesIBA 01/2022 - 01/2011
9	Toll-Like Receptor 3IBA 01/2020 - 11/2003
8	Tretinoin (Retinoic Acid)FDA LinkGeneric 02/2014 - 12/2006
6	Messenger RNA (mRNA)IBA 01/2018 - 04/2005
5	Vaccine AdjuvantsIBA 12/2018 - 12/2015
5	DNA (Deoxyribonucleic Acid)IBA 04/2018 - 01/2013
5	ChemokinesIBA 04/2018 - 08/2009
5	Pathogen-Associated Molecular Pattern MoleculesIBA 07/2017 - 08/2002
5	Viral RNAIBA 07/2017 - 09/2008
4	Neoplasm Antigens (Tumor Antigens)IBA 01/2019 - 01/2017
4	Transcription Factors (Transcription Factor)IBA 10/2017 - 12/2006
3	Immunoglobulin A (IgA)IBA 12/2018 - 12/2017
3	OvalbuminIBA 07/2018 - 01/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2018 - 01/2010
3	PAM2-CSK4IBA 01/2017 - 04/2011
3	CaspasesIBA 01/2017 - 08/2015
3	Interleukin-12 (IL 12)IBA 08/2016 - 12/2007
3	Nucleic AcidsIBA 11/2015 - 11/2014
3	Complement System Proteins (Complement)IBA 12/2012 - 02/2002
3	Monoclonal AntibodiesIBA 05/2011 - 08/2003
3	Cell Wall SkeletonIBA 07/2010 - 05/2005
3	NF-kappa B (NF-kB)IBA 08/2009 - 11/2004
3	FlagellinIBA 08/2007 - 11/2004
2	Cancer VaccinesIBA 01/2019 - 02/2016
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2018 - 09/2012
2	Hemagglutinins (Hemagglutinin)IBA 12/2017 - 12/2007
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017 - 08/2015
2	Toll-Like Receptor 2IBA 01/2017 - 12/2015
2	Phosphotransferases (Kinase)IBA 05/2016 - 01/2013
2	RNA Helicases (RNA Helicase)IBA 01/2016 - 03/2011
2	Viral DNAIBA 04/2015 - 01/2013
2	LipopeptidesIBA 02/2015 - 04/2011
2	Antigen-Antibody Complex (Immune Complex)IBA 08/2014 - 05/2011
2	Interferon-betaIBA 01/2012 - 01/2009
2	Interleukin-23 (Interleukin 23)IBA 01/2011 - 06/2008
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2011 - 06/2008
2	Small Interfering RNA (siRNA)IBA 06/2008 - 01/2006
2	Protein Isoforms (Isoforms)IBA 11/2005 - 01/2002
2	Acute-Phase Proteins (Acute-Phase Protein)IBA 03/2005 - 11/2004
1	aluminum sulfate (alum)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Programmed Cell Death 1 ReceptorIBA 01/2019
1	Complement Factor H (Factor H)IBA 01/2018
1	Immunoglobulins (Immunoglobulin)IBA 12/2017
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 12/2017
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 10/2017
1	Interleukin-12 Subunit p40IBA 10/2017
1	SmokeIBA 07/2017
1	LipopolysaccharidesIBA 01/2017
1	Toll-Like Receptor 4IBA 01/2017
1	Caspase 8 (Caspase-8)IBA 01/2017
1	Reactive Nitrogen SpeciesIBA 01/2017
1	tax Gene Products (tax Gene Product)IBA 01/2017
1	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2016

Therapy/Procedure

26	Immunotherapy 01/2020 - 11/2003
11	Therapeutics 01/2019 - 12/2007
1	Radiotherapy 04/2018
1	Intranasal Administration 01/2018
1	Subcutaneous Injections 08/2016